Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis

Inan, Saadet; Torres-Huerta, Alvaro; Jensen, Liselotte E.; Dun, Nae J.; Cowan, Alan

doi:10.1016/j.ejphar.2019.172702

Cited by 44 publications

(32 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another study demonstrated that nalbuphine attenuates pruritus and promotes skin healing through anti-inflammatory effects. 20 The antihyperalgesic actions of nalbuphine on 0-3 h (μg) 0 (0-5) 5 (0-10) 0 (0-0) 0 (0-9) 0.0321 0.0321 3-6 h (μg) 0 (0-0) 3 (0-5) 0 (0-0) 0 (0-5) 0.0040 0.0416 6-12 h (μg) 0 (0-0) 0 (0-5) 0 (0-0) 0 (0-0) 0.0736 0.6085…”

Section: Discussionmentioning

confidence: 99%

<p>Preemptive Nalbuphine Attenuates Remifentanil-Induced Postoperative Hyperalgesia After Laparoscopic Cholecystectomy: A Prospective Randomized Double-Blind Clinical Trial</p>

Hu¹,

Chen²,

Zhu³

et al. 2020

JPR

View full text Add to dashboard Cite

Background: Remifentanil-induced hyperalgesia (RIH) is a paradoxical phenomenon that may increase sensitivity to painful stimuli. Nalbuphine, which is both a μ-receptor antagonist and κ-receptor agonist, may affect RIH. The aim of this study was to evaluate the effects of nalbuphine on RIH during laparoscopic cholecystectomy. Methods: A total of 96 patients were divided into the following four groups: 0.4 μg/kg/min of remifentanil with 0.2 mg/kg of nalbuphine (HRNA), 0.4 μg/kg/min of remifentanil with saline (HRSA), 0.1 μg/kg/min of remifentanil with 0.2 mg/kg of nalbuphine (LRNA), and 0.1 μg/kg/min of remifentanil with saline (LRSA). The pain thresholds of postoperative mechanical hyperalgesia were measured with von Frey filaments. Pain intensity and analgesic consumption were recorded up to 48 h after surgery. Results: Pain thresholds on the inner forearm decreased in the HRSA group compared with the HRNA (P = 0.0167), LRNA (P = 0.0027), and LRSA (P = 0.0318) groups at 24 h after surgery. Pain thresholds on the peri-incisional area decreased in the HRSA group compared with HRNA, LRNA, and LRSA (all P < 0.0001) groups at 24 h after surgery. Patients in the HRNA group showed lower numeric rating scale scores at 1 h (P = 0.0159), 3 h (P = 0.0118), 6 h (P = 0.0213), and 12 h (P = 0.0118) than those in the HRSA group. Postoperative requirement for sufentanil was greater in the HRSA group than the HRNA group during the first 3 h (P = 0.0321) and second 3 h (P = 0.0040). Postoperative sufentanil consumption was also greater in the LRSA group than in the LRNA group during the first 3 h (P = 0.0321) and second 3 h (P = 0.0416). Conclusion: Preemptive nalbuphine can ameliorate postoperative hyperalgesia induced by high-dose remifentanil in patients undergoing laparoscopic cholecystectomy.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Preemptive Nalbuphine Attenuates Remifentanil-Induced Postoperative Hyperalgesia After Laparoscopic Cholecystectomy: A Prospective Randomized Double-Blind Clinical Trial</p>

Hu¹,

Chen²,

Zhu³

et al. 2020

JPR

View full text Add to dashboard Cite

show abstract

“…The effects of μ-agonists can be partially reversed or blocked by nalbuphine with a lower or equal analgesic dose [7]. Moreover, nalbuphine has also been effectively used to treat side effects caused by opioids, such as pruritus, bowel dysfunction and so on [7,8].…”

Section: Introductionmentioning

confidence: 99%

Effects of nalbuphine on the cardioprotective effect of morphine in rats

Wang

et al. 2021

International Journal of Cardiology

View full text Add to dashboard Cite

“…• Afamelanotide [43][44][45][46][47][48][49] • Dersimelagon (MT-7117) [50] • KdPT a [51,[54][55][56][57] • WOL074-009, WOL074-019 and WOL074-029 a [58] MC1 and additional effector pathways [85,[87][88][89][90]100] • Asimadoline [58,97,99,100] • Difelikefalin (CR845) [95] • WOL071-007 [92,94] • Compounds 5a [104,105] and 8a [104] • Compounds 3a, 4b, 5a and 5b [103] • Naltrexone [72,73,76,77] • Nalmefene [78][79][80] • Nalbuphine [81][82][83] MOR, KOR, DOR • HU-308 [109,113] • Δ 9 -THC [109,111,112] • CBD [118][119][120]…”

Section: Cutaneous Target System Indication(s)mentioning

confidence: 99%

“…A phase II/III study to assess the safety and antipruritic efficacy of matitis [83] where it was shown to have dose-dependent effects on scratching and to influence the levels of pro-and anti-inflammatory cytokines.…”

Section: Centrally-acting Opioid Receptor Modulatorsmentioning

confidence: 99%

See 1 more Smart Citation

Current and emerging treatments targeting the neuroendocrine system for disorders of the skin and its appendages

Soeberdt

Kilić

Abels

2020

Experimental Dermatology

View full text Add to dashboard Cite

The skin as a neuroendocrine organ and the role of neuroendocrine signalling in the development of disorders affecting the skin and its appendages has received increasing attention in the last years. Different neuroendocrine systems have been described in the barrier organ skin, including the thyroid system, the hypothalamicpituitary-adrenal axis, the opioid, the endocannabinoid, the cholinergic, the secosteroidogenic and the serotonergic systems. All of these systems have been implicated in the development of skin diseases, which often have an inflammatory origin. These discoveries have led to an increase in the development of new drugs targeting components of neuroendocrine signalling pathways. Additionally, attempts have been made to repurpose already approved drugs targeting neuroendocrine signalling pathways in other organs for the treatment of skin diseases. Recently published results from preclinical and clinical studies look promising and may offer improved therapies to patients suffering from skin diseases in the near future. In this review, from a pharmaceutical point of view, we focus on recent progress in synthetic drug development of compounds targeting neuroendocrine signalling in the skin and its appendages to treat skin diseases such as atopic dermatitis, psoriasis, acne, alopecia areata and hyperhidrosis.

show abstract

Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis

Cited by 44 publications

References 66 publications

<p>Preemptive Nalbuphine Attenuates Remifentanil-Induced Postoperative Hyperalgesia After Laparoscopic Cholecystectomy: A Prospective Randomized Double-Blind Clinical Trial</p>

<p>Preemptive Nalbuphine Attenuates Remifentanil-Induced Postoperative Hyperalgesia After Laparoscopic Cholecystectomy: A Prospective Randomized Double-Blind Clinical Trial</p>

Effects of nalbuphine on the cardioprotective effect of morphine in rats

Current and emerging treatments targeting the neuroendocrine system for disorders of the skin and its appendages

Contact Info

Product

Resources

About